Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Apatinib in advanced gastric adenocarcinoma
NCT04190745Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2019
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in gastric adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: 12-month Overall Survival Rate. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04190745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04190745.